Havelsan sells ADVENT CMS into Chilean Navy frigates
The Chilean frigate Almirante Blanco Encalada prior to its CMS upgrade. (Photo: Chilean Navy)
The system is intended to add enhanced operational precision to two ageing vessels.
Turkish defence technology company Havelsan has signed an agreement to provide its ADVENT combat management system (CMS) to the vessels of the Chilean Navy.
In particular, the system will be integrated into its two Karel Dorman-class or M-class frigates, Almirante Blanco Encalada and Almirante Riveros, vessels which were purchased into the Chilean Navy from the Royal Netherlands Navy in 2005 and 2007 respectively.
That means that even in their current iteration, they have served 20 and 18 years already. Updating their CMS will likely allow them to play a stronger role in the Chilean Navy in the years to come.
The
Our news & analysis is now part of Defence Insight®
A Basic-level or higher Defence Insight subscription is now required to view this content.
More from Naval Warfare
-
![Autonomy gives Turkey a chance to outflank established naval shipbuilders]()
Autonomy gives Turkey a chance to outflank established naval shipbuilders
Turkish shipbuilders have sold ships from Asia to Europe, but autonomy and swarm technology could give them a fairer fight against Western European rivals.
-
![France’s naval modernisation drives opportunities for European defence industry]()
France’s naval modernisation drives opportunities for European defence industry
Ahead of Euronaval 2026, major submarine, frigate and aircraft carrier programmes are driving investment, while future corvette replacements and growing interest in uncrewed vessels offer further opportunities for industry into the 2030s and beyond.
-
![Canada assesses security equipment changes for Polar Icebreaker Imnaryuaq]()
Canada assesses security equipment changes for Polar Icebreaker Imnaryuaq
The Canadian Department of National Defence is evaluating communications and reconnaissance changes for CCGS Imnaryuaq’s expanded maritime security role, while retaining its 2032 acceptance target.
